CASP3 and colonic neoplasm: The statistically significant up-regulation of the activity of effector caspase-3/7 occurred in the DLD-1 colon cancer cell line by ~50% and 65% following DMU-281 treatment for 72 h with 10 μM and 20 μM, respectively (Figure 2C).